When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GILD - Gilead chief defends hefty Truvada price at government hearing
Gilead Sciences Inc.
Endpoints News reports that Gilead Sciences (GILD+1.6%) CEO Daniel O'Day spent more than three hours yesterday trying to justify the $2,000/month price of Truvada (emtricitabine and tenofovir disoproxil fumarate) before a U.S. House committee on oversight and reform. The FDA approved the medication to help prevent HIV infection in high-risk people (called pre-exposure prophylaxis or PrEP) in July 2012.
More news on: Gilead Sciences, Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Healthcare stocks news,